Royal Brompton Hospital & National Heart and Lung Institute, Imperial College, London, United Kingdom.
J Thorac Cardiovasc Surg. 2013 May;145(5):1255-62. doi: 10.1016/j.jtcvs.2012.06.031. Epub 2012 Aug 11.
Pulmonary venous obstruction (PVO) is an important cause of late mortality in total anomalous pulmonary venous connection (TAPVC). We aimed to describe current practices for the management of postoperative PVO and the efficacy of the different interventional procedures.
We conducted a retrospective international collaborative population-based study involving 19 pediatric cardiac centers in the United Kingdom, Ireland, and Sweden. Patients with TAPVC born between January 1, 1998, and December 31, 2004, were identified. Patients with functionally univentricular circulation or atrial isomerism were excluded. All available data and images were reviewed.
Of 406 patients undergoing repair of TAPVC, 71 (17.5%) had postoperative PVO. The diagnosis was made within 6 months of surgery in 59 (83%) of the 71 patients. In 12, serial imaging documented change in appearance of the pulmonary veins. Good-sized pulmonary veins can progress to diffusely small veins and rarely atresia. Patients presenting after 6 months had less severe disease; all are alive at most recent follow-up. Fifty-six (13.8%) of 406 patients underwent intervention for postoperative PVO: 44 had surgical treatment and 12 had an initial catheter intervention. One half underwent 1 or more reinterventions. Three-year survival for patients with postoperative PVO was 58.7% (95% confidence intervals, 46.2%-69.2%) with a trend that those having a surgical strategy did better (P = .083). Risk factors for death included earlier presentation after TAPVC repair, diffusely small pulmonary veins at presentation of postoperative PVO, and an increased number of lung segments affected by obstruction.
Postoperative PVO tends to appear in the first 6 months after TAPVC repair and can be progressive. Early intervention for PVO may be indicated before irreversible secondary changes occur.
肺静脉梗阻(PVO)是完全性肺静脉异常连接(TAPVC)患者晚期死亡的重要原因。本研究旨在描述术后 PVO 的管理现状及不同介入治疗方法的疗效。
本研究为回顾性国际合作的基于人群的研究,纳入了英国、爱尔兰和瑞典的 19 个儿科心脏中心。入选 1998 年 1 月 1 日至 2004 年 12 月 31 日期间行 TAPVC 修复术的患者。排除功能性单心室循环或心房异构的患者。所有患者均进行了详细的临床资料和影像学资料的回顾。
406 例行 TAPVC 修复术的患者中,71 例(17.5%)出现术后 PVO。59 例(83%)患者于术后 6 个月内诊断为 PVO,其中 12 例连续影像学检查显示肺静脉外观改变。较大的肺静脉可进展为弥漫性小静脉,极少数出现肺静脉闭锁。6 个月后就诊的患者病情较轻,所有患者于最近一次随访时均存活。406 例患者中 56 例行介入治疗:44 例行手术治疗,12 例行初始导管介入治疗。其中 1/2 例患者行 1 次或多次再介入治疗。术后 PVO 患者的 3 年生存率为 58.7%(95%置信区间,46.2%-69.2%),倾向于手术治疗的患者预后更好(P=0.083)。死亡的危险因素包括 TAPVC 修复术后早期出现 PVO、术后 PVO 时肺静脉弥漫性小静脉和阻塞肺段数量增加。
术后 PVO 多发生在 TAPVC 修复术后的前 6 个月内,且呈进展性。在不可逆的继发性改变发生之前,早期干预 PVO 可能是必要的。